findmyKOL

Aditya Bardia, MD

Enriched profile

Professor of Medicine; Program Director, Breast Medical Oncology; Assistant Chief (Translational Research), Division of Hematology-Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center · David Geffen School of Medicine at UCLA

ORCID↗NPI↗
✓ Full profile
RegionSanta Monica, CA · WestSpecialtyHematology / OncologyFocusAdvanced Breast Cancer Therapies+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Aditya Bardia is Professor of Medicine; Program Director, Breast Medical Oncology; Assistant Chief (Translational Research), Division of Hematology-Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center at David Geffen School of Medicine at UCLA. OpenAlex indexes 1,145 publications with 39,602 citations (h-index 90); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

Aditya Bardia is Professor of Medicine at David Geffen School of Medicine at UCLA / UCLA Health Jonsson Comprehensive Cancer Center. The public record shows 1,145 publications with 39,602 citations (h-index 90), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 3 registered clinical trials.

  • Most recent indexed publication: 2026 · Nature nanotechnology
  • Top research focus: Advanced Breast Cancer Therapies
  • 3 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer3 trials

Research focus

OpenAlex concept fingerprint
Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Genomics and DiagnosticsCancer Treatment and PharmacologyBreast Cancer Treatment Studies

Drugs & molecules

across trials, industry payments and publications
Trodelvygeneric · SacituzumabClinical trials1Industry payments43Publications10Orserdugeneric · ElacestrantClinical trials1Industry payments3Publications5Enhertugeneric · TrastuzumabClinical trials—Industry payments21Publications4Kisqaligeneric · RibociclibClinical trials—Industry payments3Publications6Ibrancegeneric · PalbociclibClinical trials—Industry payments3Publications5Lynparzageneric · OlaparibClinical trials—Industry payments5Publications1Keytrudageneric · PembrolizumabClinical trials—Industry payments2Publications3Verzeniogeneric · AbemaciclibClinical trials—Industry payments1Publications2Perjetageneric · PertuzumabClinical trials—Industry payments3Publications—Tecentriqgeneric · AtezolizumabClinical trials—Industry payments3Publications—FulvestrantClinical trials1Industry payments—Publications—Fyarrogeneric · SirolimusClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Stemline Therapeutics, Inc.Clinical trials1Industry payments9Gilead Sciences, Inc.Clinical trials—Industry payments56AstraZeneca UK LimitedClinical trials—Industry payments44AstraZeneca Pharmaceuticals LPClinical trials—Industry payments17F. Hoffmann-La Roche AGClinical trials—Industry payments14Roche Products LimitedClinical trials—Industry payments12Sanofi-Aventis U.S. LLCClinical trials—Industry payments11E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments10Eli Lilly and CompanyClinical trials—Industry payments10Daiichi Sankyo Inc.Clinical trials—Industry payments8Novartis Pharmaceuticals CorporationClinical trials—Industry payments7Genentech USA, Inc.Clinical trials—Industry payments5Merck Sharp & Dohme LLCClinical trials—Industry payments4Genentech, Inc.Clinical trials—Industry payments3Merck Sharp & Dohme CorporationClinical trials—Industry payments3Pfizer Inc.Clinical trials—Industry payments3Genzyme CorporationClinical trials—Industry payments2Lilly USA, LLCClinical trials—Industry payments2Aadi Bioscience, Inc.Clinical trials—Industry payments1Daiichi Sankyo Company LTDClinical trials—Industry payments1Daiichi Sankyo Europe GmbHClinical trials—Industry payments1Delcath SystemsClinical trials—Industry payments1Eisai Inc.Clinical trials—Industry payments1Marengo Therapeutics, Inc.Clinical trials1Industry payments—Massachusetts General HospitalClinical trials1Industry payments—Philips Electronics North America CorporationClinical trials—Industry payments1Seagen Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,145publications

Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.

39,602citations

Total citations across indexed works.

90h-index

Hirsch index (OpenAlex). i10-index 319.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
26companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor61.3%
    Letrozole80%Exemestane20%
    Part D<11 patients
    Kinase inhibitor25.5%
    Ibrance59%Tagrisso41%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Laura M. Spring249Dejan Juric178Steven J. Isakoff175Beverly Moy173Leif W. Ellisen165Seth A. Wander129Ching‐Wei Chang116Arielle J. Medford111Sara A. Hurvitz108Sara M. Tolaney105Hope S. Rugo101Heather M. Moore100Neelima Vidula99Javier Cortés99Massimo Cristofanilli98Mary Gates97Rafael Villanueva-Vázquez96Jill Fredrickson95José Alejandro Pérez Fidalgo90X. Cynthia86Sarat Chandarlapaty84Andrzej Niemierko78Lorenzo Gerratana78Marko Velimirovic76Ciara Metcalfe74Maura N. Dickler74Jennifer Lauchle72Sravanthi Cheeti72Katherine Clifton72Andrew A. Davis71Joohyuk Sohn71Eric W. Humke71Jennifer M. Giltnane71Xiaojing Wang69Ami N. Shah68Charles S. Dai67Carolina Reduzzi66Ingrid A. Mayer65Debu Tripathy65Carlos L. Arteaga64

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/aditya-bardia-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/aditya-bardia-a1239b5a

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Aditya-Bardia-42468506

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/dradityabardia

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • X / Twitter

    twitter.com/abhealer108

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗

Mentions by others

where others cite or feature them
  • Other

    videopodcast.researchtopractice.com/breast-cancer-aditya-bardia-md-mph

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗
  • Other

    bcrf.org/researchers/aditya-bardia

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
  • Other

    breastcancer.org/podcast/enhertu-her2-low-ultralow-breast-cancer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
  • Other

    esmo.org/about-esmo/biographies/aditya-bardia

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org ↗
  • Other

    massgeneral.org/cancer-center/doctors/18953/aditya-bardia

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
  • Other

    uclahealth.org/cancer/members/aditya-bardia

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • MPH in Epidemiology

    College of Public Health, University of Iowa

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • MBBS

    All India Institute of Medical Sciences (AIIMS), New Delhi, India

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Internal Medicine Residency

    Mayo Clinic College of Medicine and Science, Rochester, MN

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Medical Oncology & Hematology Fellowship

    Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Editorial & leadership roles

journal and society appointments
  • Editor-in-Chief

    Breast Cancer Research and Treatment

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Editorial board member

    The Oncologist, Therapeutic Advances in Medical Oncology, and NPJ Precision Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Previously Director of Breast Cancer Research

    Massachusetts General Hospital Cancer Center (2021-2023), and faculty at Harvard Medical School

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.